For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
1948
The Many Missed Warnings Before Maine’s Mass Shooting
Lessons From an Unending Conflict
A Historic Strike (And Win) For Auto Workers
Israel's Invasion Begins
The Sunday Read: ‘Who Hired the Hitmen to Silence Zitácuaro?’
A New Threat: Surprise Hurricanes
Introducing ‘The War Briefing’
The House Finally Has a Speaker
Why Israel Is Delaying the Ground Invasion
The Lawyers Now Turning on Trump
The Problem With a $2 Trillion Deficit
The Sunday Read: ‘The Genius Behind Hollywood’s Most Indelible Sets’
Hamas Took Her Son
A Texas Town Wanted Tougher Border Security. Now It’s Having Regrets.
The Diplomatic Scramble to Contain the Israel-Hamas War
The Arm-Twisting, Back-Stabbing Battle for House Speaker
Voices from Gaza
The Sunday Read: ‘Is Måneskin the Last Rock Band?’
Golan’s Story
Create your
podcast in
minutes
It is Free
Up First
Consider This from NPR
Post Reports
The Ezra Klein Show
Global News Podcast